Tuesday, 16 Oct 2018

You are here

Treat-to-Target a Bust with Rheumatologists

Treat-to-target (T2T) strategy is widely advocated as an important means of optimizing treatment responses in patients with rheumatoid arthritis (RA). Even though T2T is encouraged by most guidelines, a current report shows that US Rheumatologists fail to implement T2T in their daily practice.

Rheumatology researchers from the Brigham and Women's Hospital have published the results of the TRACTION trial, which was a randomized controlled study of 641 RA patients recruited from 46 providers practicing at 11 US sites. They collected data on implementation of T2T, patient covariates, provider characteristics, site variables and also calculated a “T2T implementation score” as the percentage of features recorded.

Specifically they were seeking to identify four components of T2T from the medical records. These included:

  1. A disease activity target “treatment target”
  2. A RA disease activity measure, recommended by the ACR (CDAI, SDAI, DAS28, PAS, PASII, RAPID3)
  3. Documented shared-decision making
  4. Treatment decisions based on target and disease activity measures

Overall T2T Implementation was sub-optimal: nearly two-thirds (64%) of RA patients visits having none of the T2T components recorded, 33.1% had one component, 2.3% had two components, and 0.3% had all components.

T2T implementation differed significantly across providers and sites (P-values < 0.0001).

Older rheumatolgoists with longer experience had higher implementation score; while younger rheumatologists (fellows) had lower T2T scores.

These findings are sobering. Curtis et al have recently shown that over half of rheumatologists collect some measure, but theres little evidence that it affects decision making or therapeutics (J Rheum, http://bit.ly/2IuXWLE).  Hence, while most rheumatologists believe they practice T2T (largely because they measure something), there is little proof that they manage and treat using well defined T2T strategies. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

We were told that T2T came about because of distain of physician gestalt. The first principle was shared decision making with the patient and the physician. Except we have been doing that for centuries. T2T has some important aspects but there is a lot more to take into consideration for patient care. Our Disease Activity measures are inept and made worse by ACR indicating the DAS28ESR and DAS28CRP results are supposed to be identical. My physician gestalt does not accept that. Physician gestalt is physician judgment. Remember you are supposed to use T2T to decide to change your medication and treatment program. Well if you how do you choose? Oh yes, you use "physician gestalt!"

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.